ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P 500
6,064.23
0.05%
US Tech 100
21,054.80
-0.09%
Dow Jones
44,690.74
-0.41%
Brent Oil
74.105
-0.64%
Bitcoin
96,228.12
-0.41%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Lucid Diagnostics Inc (LUCD) Quote

Lucid Diagnostics Inc

Lucid Diagnostics Inc (LUCD)

NASDAQ
0.9592
0.0095
( 1.00% )
Updated: 14:59:39
Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Premium

Key stats and details

Current Price
0.9592
Bid
0.9501
Ask
0.9623
Volume
197,466
0.94 Day's Range 0.97
0.6301 52 Week Range 1.4594
Market Cap
56.921M
Previous Close
0.9497
Open
0.94
Last Trade
10
@
0.9501
Last Trade Time
15:00:59
Financial Volume
$ 188,459
VWAP
0.95439
Average Volume (3m)
424,830
Shares Outstanding
59,342,479
Dividend Yield
-
PE Ratio
-1.08
Earnings Per Share (EPS)
-0.89
Revenue
2.43M
Net Profit
-52.67M

About Lucid Diagnostics Inc

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically hig... Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease, also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Headquarters
Wilmington, Delaware, USA
Founded
-
Lucid Diagnostics Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker LUCD. The last closing price for Lucid Diagnostics was $0.95. Over the last year, Lucid Diagnostics shares have traded in a share price range of $ 0.6301 to $ 1.4594.

Lucid Diagnostics currently has 59,342,479 shares outstanding. The market capitalization of Lucid Diagnostics is $56.36 million. Lucid Diagnostics has a price to earnings ratio (PE ratio) of -1.08.

Ask ADVFN Intelligence (AI)

LUCD Latest News

More News

Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference PR Newswire NEW YORK, Feb. 6, 2025 NEW YORK, Feb. 6, 2025...

6 hours ago
PR Newswire (US)

Form S-8 - Securities to be offered to employees in employee benefit plans

January 31 2025
Edgar (US Regulatory)

Form S-8 - Securities to be offered to employees in employee benefit plans

January 31 2025
Edgar (US Regulatory)

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire NEW YORK, Jan. 13, 2025 Quarterly test volume of over 4,000 tests represented sequential increase of 45 percent NEW...

January 13 2025
PR Newswire (US)

Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule PR Newswire NEW YORK, Dec. 23, 2024 NEW YORK, Dec. 23, 2024 /PRNewswire/ -- Lucid...

December 23 2024
PR Newswire (US)

Form 8-K - Current report

December 20 2024
Edgar (US Regulatory)

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters PR Newswire NEW YORK, Dec. 19, 2024 Partnership launched with fully-contracted...

December 19 2024
PR Newswire (US)

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication PR Newswire NEW YORK, Dec. 11, 2024 Study demonstrates outstanding...

December 11 2024
PR Newswire (US)

Form D - Notice of Exempt Offering of Securities

December 06 2024
Edgar (US Regulatory)

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones PR Newswire NEW YORK, Dec. 3, 2024 New convertible debt...

December 03 2024
PR Newswire (US)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.06827.654320987650.8910.970.8852961370.93777935CS
40.119214.19047619050.840.970.82015740.89367609CS
12-0.0809-7.778098259781.04011.04010.75014248300.88153751CS
260.179222.97435897440.781.120.733329760.8859983CS
52-0.4608-32.45070422541.421.45940.63012583460.9029079CS
156-2.3508-71.02114803633.314.05980.63011408881.35722741CS
260-11.7908-92.476862745112.7513.50.63011568552.49074387CS

LUCD - Frequently Asked Questions (FAQ)

What is the current Lucid Diagnostics share price?
The current share price of Lucid Diagnostics is $ 0.9592
How many Lucid Diagnostics shares are in issue?
Lucid Diagnostics has 59,342,479 shares in issue
What is the market cap of Lucid Diagnostics?
The market capitalisation of Lucid Diagnostics is USD 56.36M
What is the 1 year trading range for Lucid Diagnostics share price?
Lucid Diagnostics has traded in the range of $ 0.6301 to $ 1.4594 during the past year
What is the PE ratio of Lucid Diagnostics?
The price to earnings ratio of Lucid Diagnostics is -1.08
What is the cash to sales ratio of Lucid Diagnostics?
The cash to sales ratio of Lucid Diagnostics is 23.47
What is the reporting currency for Lucid Diagnostics?
Lucid Diagnostics reports financial results in USD
What is the latest annual turnover for Lucid Diagnostics?
The latest annual turnover of Lucid Diagnostics is USD 2.43M
What is the latest annual profit for Lucid Diagnostics?
The latest annual profit of Lucid Diagnostics is USD -52.67M
What is the registered address of Lucid Diagnostics?
The registered address for Lucid Diagnostics is CORPORATION TRUST CENTER 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801
Which industry sector does Lucid Diagnostics operate in?
Lucid Diagnostics operates in the SURGICAL,MED INSTR,APPARATUS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
LTRYLottery com Inc
$ 1.28
(161.28%)
229.52M
QNTMQuantum Biopharma Ltd
$ 15.835
(84.56%)
33.85M
APPSDigital Turbine Inc
$ 4.515
(77.76%)
103.68M
LIPOLipella Pharmaceuticals Inc
$ 4.47
(73.26%)
84.03M
MSPRMSP Recovery Inc
$ 2.7904
(57.65%)
8.17M
BTAIBioXcel Therapeutics Inc
$ 0.1856
(-37.91%)
7.97M
SDASunCar Technology Group Inc
$ 5.32
(-36.97%)
4.15M
SRTSSensus Healthcare Inc
$ 5.825
(-35.21%)
2.53M
RETOReTo Eco Solutions Inc
$ 0.5399
(-32.51%)
684.59k
AVGRAvinger Inc
$ 0.385399
(-31.17%)
1.18M
MGOLMGO Global Inc
$ 0.1746
(25.61%)
316.21M
LTRYLottery com Inc
$ 1.28
(161.28%)
229.52M
NVDANVIDIA Corporation
$ 127.5501
(2.18%)
190.71M
CYNCYNGN Inc
$ 0.0823
(0.37%)
125.74M
RIMEAlgorhythm Holdings Inc
$ 0.0216
(3.35%)
111.37M

LUCD Discussion

View Posts
georgie18 georgie18 3 months ago
LUCD...$1.08...Off my .90 alert...🥳

georgie18

Member Level
Re: georgie18 post# 384972

Thursday, November 07, 2024 8:57:15 AM

Post#
385327
of 385451
LUCD...$1.05...🥳...NEW YORK, Nov. 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the manuscript for its multicenter ESOGUARD BE-1 study has been accepted for publication in The American Journal of Gastroenterology, the official journal of the American College of Gastroenterology (ACG). This is the fourth publication presenting clinical validation data for Lucid's EsoGuard® Esophageal DNA Test, and the second to demonstrate its strong performance in an intended-use screening population. Consistent with previous studies, EsoGuard showed high sensitivity and negative predictive value in detecting esophageal precancer (Barrett's Esophagus or BE).

georgie18

Member Level
Re: None

Tuesday, October 29, 2024 9:48:42 AM

Post#
6
of 7
LUCD...9621...Trying Red to Green here...🥳

georgie18

Member Level
Re: None

Tuesday, October 29, 2024 8:23:21 AM

Post#
384965
of 384971
LUCD...90 ...https://schrts.co/DyzNKhGQ ...Break/hold 98 and I think she will rip...🥳
👍️0
chemist72 chemist72 3 months ago
What is the MoIDX Medicare Program?
https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?lcdid=35025
👍️0
georgie18 georgie18 3 months ago
LUCD...$1.05...🥳...NEW YORK, Nov. 7, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced that the manuscript for its multicenter ESOGUARD BE-1 study has been accepted for publication in The American Journal of Gastroenterology, the official journal of the American College of Gastroenterology (ACG). This is the fourth publication presenting clinical validation data for Lucid's EsoGuard® Esophageal DNA Test, and the second to demonstrate its strong performance in an intended-use screening population. Consistent with previous studies, EsoGuard showed high sensitivity and negative predictive value in detecting esophageal precancer (Barrett's Esophagus or BE).

georgie18

Member Level
Re: None

Tuesday, October 29, 2024 9:48:42 AM

Post#
6
of 7
LUCD...9621...Trying Red to Green here...🥳

georgie18

Member Level
Re: None

Tuesday, October 29, 2024 8:23:21 AM

Post#
384965
of 384971
LUCD...90 ...https://schrts.co/DyzNKhGQ ...Break/hold 98 and I think she will rip...🥳
👍️0
georgie18 georgie18 3 months ago
LUCD...9621...Trying Red to Green here...🥳

georgie18

Member Level
Re: None

Tuesday, October 29, 2024 8:23:21 AM

Post#
384965
of 384971
LUCD...90 ...https://schrts.co/DyzNKhGQ ...Break/hold 98 and I think she will rip...🥳
👍️0
georgie18 georgie18 3 months ago
LUCD...90 ...https://schrts.co/DyzNKhGQ ...Break/hold 98 and I think she will rip...🥳
👍️0
Monksdream Monksdream 11 months ago
LUCD new 52 lo
👍️0
Monksdream Monksdream 1 year ago
LUCD new 52 week low
👍️0
ErnieBilco ErnieBilco 3 years ago
Should have listened to the chart telling me lower but I bought some at $2.39 and $2.21 for a starter. It has a $9+ PT
👍️0
makinezmoney makinezmoney 3 years ago
$LUCD: Not the EV Car Company...............


But you can easily get confused.



Now at $7.30 here in PreMarket



https://www.luciddx.com/





GO $LUCD
👍️0

Your Recent History

NASDAQ
LUCD
Lucid Diagnostics
NASDAQ
ABLFAXX
Royal Bank of Canada Poi...
DOWI
DJC2LBRP
DJ Commodity Index 2X Le...
LSE
MMH
Marshall Motor
LSE
BTIG
Troy Income & Growth
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads